CU-Boulder to fly antibiotic experiment, education project on ants to space station

NASA Television will provide live coverage of the launch of Orbital Sciences Corp.'s commercial Cygnus spacecraft on Tuesday, Jan. 7 from NASA's Wallops Flight Facility in Virginia, which will be carrying two University of Colorado Boulder payloads to the International Space Station.

The two CU-Boulder payloads -- a biomedical antibiotic experiment and an educational K-12 experiment involving ant behavior in microgravity -- are slated to be launched aboard Orbital Sciences Corp.'s Antares rocket at 11:55 a.m. MST. Both experiments were designed by BioServe Space Technologies, a NASA-funded center in CU-Boulder's aerospace engineering sciences department.

The CU-Boulder biomedical experiment was designed to test the effectiveness of antibiotics in space. Past experiments by CU-Boulder and other institutions have shown bacterial susceptibility to antibiotics is significantly reduced during spaceflight, although the reason is not yet known, said CU-Boulder Associate Professor David Klaus, principal investigator on the project.

Klaus said the investigation will examine changes in the gene expression of the bacteria E. coli during exposure to different concentrations of antibiotics while in the microgravity environment of space. The hope is to locate particular genes that are key to resisting antibiotics, which could lead to improved testing on Earth as well as new drug targets or new approaches to understanding antibiotic resistance in certain diseases or infections, said Klaus.

"Previous studies carried out in microgravity have shown that bacteria are able to grow in what normally would be an inhibitory concentration of the antibiotic," said Klaus. "This investigation is aimed at characterizing the genetic basis for this response in the weightless environment of space with the intent of applying any insight gained toward combating the increasing emergence of drug-resistant pathogens here on Earth."

Co-investigators on the project include BioServe Director Louis Stodieck, a research professor in aerospace engineering, and Shawn Levy, a researcher at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. The research effort also involves CU-Boulder doctoral candidate Luis Zea.

Bacterial resistance to antibiotics kills 100,000 Americans every year and represents a roughly $20 billion expense to the U.S. government in excess health care costs, said Klaus. The experiments will be undertaken using spaceflight test tubes contained in the Commercial Generic Bioprocessing Apparatus, or CGBA, an automated, suitcase-sized incubator, all designed and built by BioServe.

The second experiment launching to ISS is known as Ants in Space, which examines foraging patterns based on the density of the common Pavement Ant, said BioServe Business Development Manager and Education Program Director Stefanie Countryman. "Past experiments by Professor Deborah Gordon, principal investigator on this project, have shown that some ant species have the ability to search areas collectively without individual communication. When ant densities are high, each ant thoroughly searches one small area in a circular, "random" walk, she said. When ant densities are low, each ant searches by walking in a relatively straight line, allowing it to cover more ground.

"Ants assess their own density at the rate at which they meet," said Countryman, who said the eight individual ant habitats on ISS will be loaded with roughly 100 ants each. "The experiment examines whether in microgravity ants will use the rate at which they meet to assess density, and so use straighter paths in the larger habitat areas. The results will be compared to ground controls, which in this case will include ant habitats in hundreds of K-12 classrooms around the world."